Annovis Bio Future Growth
Future criteria checks 0/6
Annovis Bio's earnings are forecast to decline at 3.1% per annum while its annual revenue is expected to grow at 66.7% per year. EPS is expected to grow by 46% per annum. Return on equity is forecast to be -84.1% in 3 years.
Key information
-3.1%
Earnings growth rate
46.0%
EPS growth rate
Biotechs earnings growth | 24.6% |
Revenue growth rate | 66.7% |
Future return on equity | -84.1% |
Analyst coverage | Low |
Last updated | 13 Jun 2024 |
Recent future growth updates
Recent updates
Annovis Bio: Alzheimer's Phase 2/3 Topline Readout Puts Future For Buntanetap Into Question
May 02Annovis: Potentially Encouraging Anecdotes, Weighing Phase 3 Parkinson's Prospects
Feb 12Annovis And Alzheimer's Disease: The Best-Laid Plans
Jan 30Annovis Bio: Buntanetap Likely To Disappoint In The Upcoming AD And PD Clinical Trials
Jan 20Annovis: Due Diligence Prior To Parkinson's And Alzheimer's Readouts
Oct 16Annovis Bio (NYSE:ANVS) Will Have To Spend Its Cash Wisely
Sep 08Annovis Bio: End Of 2023 Parkinson's Data Could Shift Momentum
Jun 28Annovis wins EU nod to expand late-stage trial for Parkinson's candidate
Feb 08We Think Annovis Bio (NYSE:ANVS) Can Afford To Drive Business Growth
Jan 28Annovis gains amid ‘strong’ enrollment in late-stage trial Parkinson's drug
Jan 25Annovis: Late-Stage Parkinson's Disease Trial Advancement Makes It Worth A Look
Oct 06We're Hopeful That Annovis Bio (NYSE:ANVS) Will Use Its Cash Wisely
Sep 15Annovis Bio announces publication of three U.S. patents covering lead asset
Sep 13Annovis Bio gains as dosing begins in late-stage trial for Parkinson’s candidate
Aug 24Annovis Bio wins FDA nod to begin late-stage study for Parkinson's candidate
Jul 07Annovis Bio (NYSE:ANVS) Is In A Good Position To Deliver On Growth Plans
May 14We Think Annovis Bio (NYSE:ANVS) Can Afford To Drive Business Growth
Feb 10Here's Why We're Not Too Worried About Annovis Bio's (NYSEMKT:ANVS) Cash Burn Situation
Apr 16Do Institutions Own Annovis Bio, Inc. (NYSEMKT:ANVS) Shares?
Feb 23We Think Annovis Bio (NYSEMKT:ANVS) Can Afford To Drive Business Growth
Jan 01Earnings and Revenue Growth Forecasts
Date | Revenue | Earnings | Free Cash Flow | Cash from Op | Avg. No. Analysts |
---|---|---|---|---|---|
12/31/2026 | 8 | -69 | -58 | -56 | 4 |
12/31/2025 | N/A | -47 | -47 | -45 | 5 |
12/31/2024 | N/A | -19 | -24 | -23 | 5 |
3/31/2024 | N/A | -48 | -35 | -35 | N/A |
12/31/2023 | N/A | -56 | -40 | -40 | N/A |
9/30/2023 | N/A | -42 | -34 | -34 | N/A |
6/30/2023 | N/A | -33 | -29 | -29 | N/A |
3/31/2023 | N/A | -30 | -26 | -26 | N/A |
12/31/2022 | N/A | -25 | -17 | -17 | N/A |
9/30/2022 | N/A | -24 | -15 | -15 | N/A |
6/30/2022 | N/A | -20 | -13 | -13 | N/A |
3/31/2022 | N/A | -17 | -10 | -10 | N/A |
12/31/2021 | N/A | -14 | -9 | -9 | N/A |
9/30/2021 | N/A | -10 | -8 | -8 | N/A |
6/30/2021 | N/A | -8 | -7 | -7 | N/A |
3/31/2021 | N/A | -8 | -5 | -5 | N/A |
12/31/2020 | N/A | -5 | -4 | -4 | N/A |
9/30/2020 | N/A | -4 | -3 | -3 | N/A |
6/30/2020 | N/A | -3 | -2 | -2 | N/A |
3/31/2020 | N/A | -1 | -1 | -1 | N/A |
12/31/2019 | N/A | -1 | 0 | 0 | N/A |
9/30/2019 | N/A | -1 | -1 | -1 | N/A |
6/30/2019 | N/A | -1 | -1 | -1 | N/A |
3/31/2019 | N/A | -1 | -1 | -1 | N/A |
12/31/2018 | N/A | -1 | -1 | -1 | N/A |
Analyst Future Growth Forecasts
Earnings vs Savings Rate: ANVS is forecast to remain unprofitable over the next 3 years.
Earnings vs Market: ANVS is forecast to remain unprofitable over the next 3 years.
High Growth Earnings: ANVS is forecast to remain unprofitable over the next 3 years.
Revenue vs Market: ANVS is forecast to have no revenue next year.
High Growth Revenue: ANVS is forecast to have no revenue next year.
Earnings per Share Growth Forecasts
Future Return on Equity
Future ROE: ANVS is forecast to be unprofitable in 3 years.